Page last updated: 2024-11-08

serine and Bone Cancer

serine has been researched along with Bone Cancer in 16 studies

Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.

Research Excerpts

ExcerptRelevanceReference
"We recently reported that in Ewing sarcoma, MLL1 (lysine methyltransferase 2A, KMT2A) and menin are overexpressed and function as oncogenes."5.48Menin regulates the serine biosynthetic pathway in Ewing sarcoma. ( Bankhead, AR; Cierpicki, T; Grembecka, J; Halbrook, CJ; Kerk, S; Klossowski, S; Kremer, D; Lawlor, ER; Lee, HJ; Ljungman, M; Lyssiotis, CA; Magnuson, B; Sud, S; Svoboda, LK; Teh, SSK; Thomas, D; Treichel, S; Zebolsky, A; Zhang, L, 2018)
"Since bone metastatic breast cancer is an incurable disease, causing significant morbidity and mortality, an understanding of the underlying molecular mechanisms would be highly valuable."5.37Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. ( Edgren, H; Guise, T; Käkönen, SM; Kallioniemi, O; Kohonen, P; Nees, M; Pollari, S; Sara, H; Wolf, M, 2011)
"We revealed that expression of miR-659-3p was significantly downregulated in osteosarcoma compared with normal bone cells and was inversely correlated with serine-arginine protein kinase 1 (SRPK1) expression."4.12MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1. ( Gong, Y; Wei, ZR, 2022)
"Ewing sarcomas are driven by EWS-ETS fusions, most commonly EWS-FLI1, which promotes widespread metabolic reprogramming, including activation of serine biosynthesis."4.02EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. ( Apfelbaum, AA; Bradin, J; Chen, D; Cierpicki, T; Garcia, AX; Grembecka, J; Haarer, E; Hawkins, AG; Jiménez, JA; Kumar, A; Lawlor, ER; Lyssiotis, CA; Nwosu, ZC; Purohit, T; Ruiz, RO; Svoboda, LK, 2021)
"Ascochlorin, a prenylphenol antitumor antibiotic, profoundly increases the expression of endogenous p53 by increasing protein stability in the human osteosarcoma cells and human colon cancer cells."3.75Ascochlorin activates p53 in a manner distinct from DNA damaging agents. ( Chang, HW; Chang, YC; Furukawa, C; Jeong, JH; Kim, CH; Lee, IS; Magae, J; Min, KS; Nakajima, H; Otsuka, K; Park, KK; Taki, K; Tomita, M, 2009)
"We recently reported that in Ewing sarcoma, MLL1 (lysine methyltransferase 2A, KMT2A) and menin are overexpressed and function as oncogenes."1.48Menin regulates the serine biosynthetic pathway in Ewing sarcoma. ( Bankhead, AR; Cierpicki, T; Grembecka, J; Halbrook, CJ; Kerk, S; Klossowski, S; Kremer, D; Lawlor, ER; Lee, HJ; Ljungman, M; Lyssiotis, CA; Magnuson, B; Sud, S; Svoboda, LK; Teh, SSK; Thomas, D; Treichel, S; Zebolsky, A; Zhang, L, 2018)
"For the femur bone cancer model, NCTC 2472 tumor cells were injected into the medullary cavity of the distal femur of C3H/HeN mice."1.40Relief of cancer pain by glycine transporter inhibitors. ( Dohi, T; Kanematsu, T; Kitayama, T; Morita, K; Motoyama, N; Shiraishi, S; Uezono, Y, 2014)
"ERα is critical in many breast tumors and is inhibited by antiestrogens such as tamoxifen in cancer therapy."1.38Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. ( de Leeuw, R; Houtman, R; Martens, JW; Melchers, D; Michalides, R; Neefjes, J; Rondaij, M; Ruijtenbeek, R; Verwoerd, D, 2012)
"Since bone metastatic breast cancer is an incurable disease, causing significant morbidity and mortality, an understanding of the underlying molecular mechanisms would be highly valuable."1.37Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. ( Edgren, H; Guise, T; Käkönen, SM; Kallioniemi, O; Kohonen, P; Nees, M; Pollari, S; Sara, H; Wolf, M, 2011)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.25)18.7374
1990's1 (6.25)18.2507
2000's3 (18.75)29.6817
2010's8 (50.00)24.3611
2020's3 (18.75)2.80

Authors

AuthorsStudies
Gong, Y1
Wei, ZR1
Issaq, SH1
Mendoza, A1
Kidner, R1
Rosales, TI1
Duveau, DY1
Heske, CM1
Rohde, JM1
Boxer, MB1
Thomas, CJ1
DeBerardinis, RJ1
Helman, LJ1
Jiménez, JA1
Apfelbaum, AA1
Hawkins, AG1
Svoboda, LK2
Kumar, A1
Ruiz, RO1
Garcia, AX1
Haarer, E1
Nwosu, ZC1
Bradin, J1
Purohit, T1
Chen, D1
Cierpicki, T2
Grembecka, J2
Lyssiotis, CA2
Lawlor, ER2
Teh, SSK1
Sud, S1
Kerk, S1
Zebolsky, A1
Treichel, S1
Thomas, D1
Halbrook, CJ1
Lee, HJ1
Kremer, D1
Zhang, L1
Klossowski, S1
Bankhead, AR1
Magnuson, B1
Ljungman, M1
Sen, N1
Cross, AM1
Lorenzi, PL1
Khan, J1
Gryder, BE1
Kim, S1
Caplen, NJ1
Ding, J1
Li, T1
Wang, X1
Zhao, E1
Choi, JH1
Yang, L1
Zha, Y1
Dong, Z1
Huang, S1
Asara, JM1
Cui, H1
Ding, HF1
Motoyama, N1
Morita, K1
Shiraishi, S1
Kitayama, T1
Kanematsu, T1
Uezono, Y1
Dohi, T1
Wu, Q1
Paul, A1
Su, D1
Mehmood, S1
Foo, TK1
Ochi, T1
Bunting, EL1
Xia, B1
Robinson, CV1
Wang, B1
Blundell, TL1
Gorska-Ponikowska, M1
Perricone, U1
Kuban-Jankowska, A1
Lo Bosco, G1
Barone, G1
Jeong, JH1
Nakajima, H1
Magae, J1
Furukawa, C1
Taki, K1
Otsuka, K1
Tomita, M1
Lee, IS1
Kim, CH1
Chang, HW1
Min, KS1
Park, KK2
Chang, YC1
Pollari, S1
Käkönen, SM1
Edgren, H1
Wolf, M1
Kohonen, P1
Sara, H1
Guise, T1
Nees, M1
Kallioniemi, O1
Houtman, R1
de Leeuw, R1
Rondaij, M1
Melchers, D1
Verwoerd, D1
Ruijtenbeek, R1
Martens, JW1
Neefjes, J1
Michalides, R1
Tanaka, H1
Yoshida, K1
Okamura, H1
Morimoto, H1
Nagata, T1
Haneji, T1
Whitfield, JF1
Morley, P1
Willick, G1
Langille, R1
Ross, V1
MacLean, S1
Barbier, JR1
Barrientes, S1
Cooke, C1
Goodrich, DW1
Mäsiar, PJ1
Medeková, E1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia[NCT04067336]Phase 1/Phase 2199 participants (Anticipated)Interventional2019-09-12Recruiting
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation[NCT04065399]Phase 1/Phase 2440 participants (Anticipated)Interventional2019-11-05Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

16 other studies available for serine and Bone Cancer

ArticleYear
MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.
    BMC cancer, 2022, Aug-29, Volume: 22, Issue:1

    Topics: 3' Untranslated Regions; Animals; Arginine; Arginine Kinase; Bone Neoplasms; Cell Line, Tumor; Cell

2022
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:7

    Topics: Animals; Apoptosis; Bone Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplast

2020
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Molecular cancer research : MCR, 2021, Volume: 19, Issue:7

    Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro

2021
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Molecular cancer research : MCR, 2021, Volume: 19, Issue:7

    Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro

2021
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Molecular cancer research : MCR, 2021, Volume: 19, Issue:7

    Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro

2021
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Molecular cancer research : MCR, 2021, Volume: 19, Issue:7

    Topics: Activating Transcription Factor 4; Biosynthetic Pathways; Bone Neoplasms; Cell Line, Tumor; Cell Pro

2021
Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
    The Journal of pathology, 2018, Volume: 245, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Energy Metabol

2018
EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
    Molecular carcinogenesis, 2018, Volume: 57, Issue:10

    Topics: Amino Acid Transport System ASC; Aminohydrolases; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell

2018
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation.
    Cell metabolism, 2013, Dec-03, Volume: 18, Issue:6

    Topics: Animals; Autophagy; Azepines; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; E

2013
Relief of cancer pain by glycine transporter inhibitors.
    Anesthesia and analgesia, 2014, Volume: 119, Issue:4

    Topics: Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Drug Therapy, Combination; Glycine Plasma Mem

2014
Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites.
    Molecular cell, 2016, Feb-04, Volume: 61, Issue:3

    Topics: Amino Acid Sequence; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; BRCA1 Protein; Carrier

2016
2-methoxyestradiol impacts on amino acids-mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor.
    Journal of cellular physiology, 2017, Volume: 232, Issue:11

    Topics: 2-Methoxyestradiol; Antineoplastic Agents; Binding Sites; Bone Neoplasms; Breast Neoplasms; Cell Mov

2017
Ascochlorin activates p53 in a manner distinct from DNA damaging agents.
    International journal of cancer, 2009, Jun-15, Volume: 124, Issue:12

    Topics: Adenosine Triphosphate; Alkenes; Antibiotics, Antineoplastic; Ataxia Telangiectasia Mutated Proteins

2009
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:2

    Topics: Animals; Blotting, Western; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Differentiation;

2011
Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Estrogen Recept

2012
Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappaB in human osteoblastic osteosarcoma MG63 cells.
    International journal of oncology, 2007, Volume: 31, Issue:2

    Topics: Apoptosis; Binding Sites; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans

2007
Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1997, Volume: 12, Issue:8

    Topics: Adenylyl Cyclases; Analysis of Variance; Animals; Bone Development; Bone Neoplasms; Disease Models,

1997
Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function.
    Oncogene, 2000, Jan-27, Volume: 19, Issue:4

    Topics: Bone Neoplasms; Cell Cycle; Cell Line; Cyclin-Dependent Kinases; Genes, Retinoblastoma; Glutamic Aci

2000
The role of serine and glutamine in the metabolism of malignant bone tumors and their significance in the diagnosis and prognosis of bone tumors.
    Neoplasma, 1988, Volume: 35, Issue:2

    Topics: Amino Acids; Biomarkers, Tumor; Bone Neoplasms; Glutamine; Humans; Prognosis; Reference Values; Seri

1988